-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓USDBörse
Dir gefallen die Informationen zu NYSE Arca Defense Index (Settle?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF-Sparplan im Quartal bleibt dein Depot für Immer kostenfrei:
Zum Angebot
Dir gefallen die Informationen zu NYSE Arca Defense Index (Settle?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos ETFs zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu NYSE Arca Defense Index (Settle?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen ETF-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
54 News & Informationen zur NYSE Arca Defense Index (Settle Aktie
Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase
NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical,…
Intersect ENT : Medtronic to Acquire Intersect ENT
DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ — Medtronic plc , the global leader in medical technology, today announced that it has entered into a definitive agreement with… | August 6, 2021
Medtronic to Acquire Intersect ENT
/PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with…
National Kidney Foundation and Labcorp Data Show Millions Aren't Tested for Kidney Disease
/PRNewswire/ — New data suggest that millions of patients most at-risk for life-threatening kidney disease are unaware they have it because they are not…
Rigel Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update (Form 8-K)
Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update
–
Net product sales of $17.1 million and total… | August 3, 2021
Dexcom Reports Second Quarter 2021 Financial Results
Dexcom Reports Second Quarter 2021 Financial Results | Nachricht | finanzen.net
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
/PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and…
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
MINDCURE's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the p…
Manulife enhances MOVE app to help make healthy habits stick
New 'Self-Set Target' lets customers set goals, achieve streaks, and earn rewards from Asia's leading health, wellness, and lifestyle brands.This …
GlaxoSmithKline : Shingrix approved in the US for prevention of shingles in immunocompromised adults
For media and investors only
Issued: Philadelphia, London
GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Shingrix … | July 26, 2021
Shingrix approved in the US for prevention of shingles in immunocompromised adults
/PRNewswire/ — GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant,…
Shingrix approved in the US for prevention of shingles in immunocompromised adults
LONDON and PHILADELPHIA, July 26, 2021 /PRNewswire/ — GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has appr…
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
— Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD and low doses (2 x 10^11 vg/eye and lower); no longer…
Dicerna Announces Interim Results From Phase 1 Trial Of Belcesiran For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)